首页> 外文期刊>Stem cells international >Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Inhibit Endometrial Cancer Cell Proliferation and Migration through Delivery of Exogenous miR-302a
【24h】

Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Inhibit Endometrial Cancer Cell Proliferation and Migration through Delivery of Exogenous miR-302a

机译:人的脐带间充质干细胞衍生的细胞外囊囊泡通过产外萌发MiR-302a抑制子宫内膜癌细胞增殖和迁移

获取原文
获取原文并翻译 | 示例
       

摘要

MicroRNAs (miRNAs) are potential therapeutic targets in endometrial cancer, but the difficulties associated with their delivery to tumor target cells have hampered their applications. Human umbilical cord mesenchymal stem cells (hUCMSCs) have a well-recognized tumor-homing ability, emphasizing the capacity of tumor-targeted delivery of extracellular vesicles. hUCMSCs release extracellular vesicles rich in miRNAs, which play a vital role in intercellular communication. The purpose of this study was to verify a potential tumor suppressor microRNA, miR-302a, and engineered hUCMSC extracellular vesicles enriched with miR-302a for therapy of endometrial cancer. Here, we observed that miR-302a was significantly downregulated in endometrial cancer tissues when compared with adjacent tissues. Overexpression of miR-302a in endometrial cancer cells robustly suppressed cell proliferation and migration. Meanwhile, the proliferation and migration were significantly inhibited in endometrial cancer cells when cultured with miR-302a-loaded extracellular vesicles derived from hUCMSCs. Importantly, our data showed that engineered extracellular vesicles rich in miR-302 significantly inhibited the expression of cyclin D1 and suppressed AKT signaling pathway in endometrial cancer cells. These results suggested that exogenous miR-302a delivered by hUCMSC-derived extracellular vesicles has exciting potential as an effective anticancer therapy.
机译:MicroRNAs(miRNA)是子宫内膜癌的潜在治疗靶标,但与其交付给肿瘤靶细胞相关的困难阻碍了他们的应用。人的脐带间充质干细胞(HUCMSCs)具有公认的肿瘤归巢能力,强调肿瘤靶向细胞外囊囊泡的能力。 Hucmscs释放富含MiRNA的细胞外囊,这在细胞间通信中起着至关重要的作用。本研究的目的是验证潜在的肿瘤抑制microRNA,miR-302a和工程化Hucmsc细胞外囊泡富含miR-302a,用于治疗子宫内膜癌。这里,我们观察到与相邻组织相比,MiR-302a在子宫内膜癌组织中显着下调。内膜癌细胞中miR-302a的过表达鲁棒地抑制细胞增殖和迁移。同时,当用衍生自Hucmscs的MiR-302a加载的细胞外囊泡培养时,子宫内膜癌细胞中的增殖和迁移显着抑制。重要的是,我们的数据显示,富含MIR-302的工程细胞外囊泡显着抑制了细胞周期蛋白D1和抑制子宫内膜癌细胞中的AKT信号通路的表达。这些结果表明,Hucmsc衍生的细胞外囊泡提供的外源miR-302a具有令人兴奋的抗癌疗法。

著录项

  • 来源
    《Stem cells international》 |2019年第2期|共11页
  • 作者单位

    Jinzhou Med Univ Dept Obstet &

    Gynecol Affiliated Hosp 3 Jinzhou 121001 Liaoning Peoples R;

    Dalian Med Univ Dept Obstet &

    Gynecol Dalian Obstet &

    Gynecol Hosp Dalian Matern Hosp Dalian;

    Tongji Univ Sch Med Clin &

    Translat Res Ctr Shanghai Matern &

    Infant Hosp 1 Shanghai 200040;

    Tongji Univ Sch Med Clin &

    Translat Res Ctr Shanghai Matern &

    Infant Hosp 1 Shanghai 200040;

    Jinzhou Med Univ Affiliated Hosp 1 Dept Obstet &

    Gynecol Key Lab Follicular Dev &

    Reprod Hlth;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物工程学(生物技术);
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号